Synaptobrevin Inhibitors
1 drugsAbout Synaptobrevin
Synaptobrevin (VAMP2) is a key protein in neurotransmitter release at nerve synapses. As a core component of the SNARE complex, it mediates synaptic vesicle fusion with the presynaptic membrane, enabling neurotransmitter release.
Synaptobrevin's critical role in neuronal communication makes it a potential therapeutic target. Currently, there is no genetic evidence directly linking Synaptobrevin to specific diseases.
MYOBLOC (ELAN PHARM) is the only FDA-approved drug targeting Synaptobrevin, approved in 2000. It is a biologic (other) and has applications in 'Other' therapeutic areas.
Top Synaptobrevin Drugs
ELAN PHARM is the only company with an approved drug targeting Synaptobrevin.
The lack of competitors suggests either high entry barriers or untapped potential in targeting Synaptobrevin.
Synaptobrevin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Synaptobrevin, using biologic (other) modality.
Exploring small molecule or antibody modalities could diversify the therapeutic options for Synaptobrevin.
Synaptobrevin Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Synaptobrevin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 6 | 0 | 2 | 100% |
| Phase 2 | 10 | 3 | 5 | 2 | 38% |
| Phase 3 | 9 | 6 | 2 | 1 | 75% |
| Phase 4 | 5 | 3 | 1 | 1 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Synaptobrevin Drug Approval Timeline (2000 - 2000)
The first and only drug, MYOBLOC, was approved in 2000.
The lack of recent approvals indicates a potentially saturated market or challenges in developing new Synaptobrevin-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 25 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Synaptobrevin. A trial counts if an approved drug acting on Synaptobrevin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.